Cheryl Townsend
Women's Health · Farmington, MONPI 1548315914
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 34.0% of the total. Reporting peaked in 2024 at $1,663 and has fallen 77.0% since, to $382 in 2025. Among women's health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$359
- Neurocrine Biosciences, Inc.$225
- Novo Nordisk$216
- GSK$192
- Boehringer Ingelheim$161
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,124100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $1,401 |
| Lilly USA, LLC | 19 | $359 |
| Neurocrine Biosciences, Inc. | 9 | $225 |
| Novo Nordisk | 15 | $216 |
| GSK | 12 | $192 |
| Boehringer Ingelheim | 9 | $161 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $155 |
| Sumitomo Pharma America, Inc. | 8 | $125 |
| Pfizer | 6 | $102 |
| Lundbeck LLC | 5 | $97 |
| Nestle Healthcare Nutrition Inc. | 2 | $94 |
| Teva Pharmaceuticals USA, Inc. | 5 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $84 |
| AstraZeneca | 5 | $80 |
| Axsome Therapeutics, Inc. | 3 | $74 |
| Johnson & Johnson | 3 | $66 |
| Bayer | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Dexcom, Inc. | 3 | $49 |
| Astellas Pharma US Inc | 3 | $46 |
| Gilead | 2 | $43 |
| Novartis | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Ardelyx, Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Merck | 2 | $27 |
| Seqirus USA Inc | 1 | $21 |
| Mylan Specialty L.p. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Medtronic | 1 | $16 |
| Exeltis, USA Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Organon | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$100
How this compares
$4,124 in reported general payments places this provider in the 90th percentile of 208 women's health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 22 | $15,906 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,693 |
| Estradiol | 54 | $1,761 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,174 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,156 |
| SynthroidLevothyroxine Sodium | 14 | $769 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 43 | $710 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 12 | $666 |
| Celecoxib | 11 | $612 |
| Omeprazole | 61 | $558 |
| Levothyroxine Sodium | 112 | $538 |
| Nystatin | 58 | $532 |
| Fluconazole | 65 | $445 |
| Ondansetron OdtOndansetron | 34 | $438 |
| Medroxyprogesterone Acetate | 11 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $161 | $15,90622 claims |
| GSKTrelegy Ellipta | $192 | $7,69312 claims |
| AbbVieSynthroid | $1,401 | $76914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 208 women's health providers in Missouri.
Other women's health in Farmington
- Kathryn SimoneBlue Springs$192K
- Nealya Bell-SilvaSaint Louis$107K
- Susan HoffstetterSaint Louis$39K
- Karla WilmotIndependence$22K
- Janice EislebenSaint Louis$16K
- Susan Mitchell-DerenskiSaint Louis$14K
- Amanda SchillySaint Louis$8K
- Jeanette ShanholtzerLees Summit$7K
- Kris ScalfSaint Louis$7K
- Savannah HayesSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.